ConcertAI Launches New Generative and Agentic AI-Powered Precision Suite™ Accelerating Oncology Insights and Actions for Healthcare and Life Sciences
The Precision Suite leverages CARAai's multi-modal, AI-curated data architecture to translate complex medical and genomic data into precise, real-world applications. These applications are built on a unique platform that is comprised of assistants, agents, LLMs and LRMs that are specifically designed and trained to support use cases in life sciences and healthcare. Its seamless integration of diverse data types enables life sciences teams to respond faster, make evidence-backed decisions, and maximize strategic impact. At launch, the suite includes three powerful applications tailored to distinct use cases across the healthcare ecosystem.
Precision Explorer™ empowers Health Economics and Outcomes Research (HEOR), epidemiology, and medical teams to uncover actionable insights within minutes. Generative AI and intuitive interfaces streamline cohort creation, outcomes analysis, and hypothesis testing, unlocking insights 2x faster than traditional methods, saving customers millions. With its ability to leverage curated oncology data and align with industry guidelines, such as ASCO® Standards, Precision Explorer ensures high-quality, citation-backed results.
Precision Trials™ transforms clinical trial operations by enabling smarter, faster decisions in study design, site selection, and patient recruitment. Powered by dynamic AI agents, this solution reduces costly trial amendments, improves site performance, and ensures diversity and enrollment goals are met. CARAai's advanced data-processing capabilities provide real-time assessments, shortening trial timelines with the potential to deliver $4M+ in cost savings for Phase II and III studies.
Precision GTM™ focuses on commercialization strategies for oncology therapies, unifying fragmented clinical, claims, and social determinants of health data. Harnessing CARAai's multi-modal insights, this platform enables brand teams to track the real-time standard of care, physician trends, and treatment pathways. By accelerating decision-making and enabling timely engagement, Precision GTM empowers teams to achieve faster, more impactful market execution while generating up to $7M in value for a typical oncology brand.
Precision360™, the backbone of ConcertAI's Precision Suite™, integrates EMR and genomic data alongside claims and social determinants of health information to create a revolutionary new RWD dataset. With AI-curation and a recency of less than a week, it provides real-time access to actionable insights, eliminating delays in oncology research and decisions. Designed for speed and efficiency, Precision360 provides accuracy and reliability, even in complex, unstructured datasets.
'Precision Suite is a testament to our commitment to innovation and patient-first outcomes,' said Eron Kelly, CEO of ConcertAI. 'Its ability to process complex, diverse datasets in near real-time has allowed us to deliver immediately actionable insights that will save customers millions in costs, while accelerating their time to market for life saving therapeutics. These new SaaS products are all built on our CARAai platform, the leading agentic AI platform built specifically for the needs of the life sciences enterprise.'
'ConcertAI serves 75% of the top life science companies and more than 50% of the largest global healthcare providers,' said Jeff Elton, Ph.D., Vice Chairman of ConcertAI. 'This launch signifies the evolution of ConcertAI from providing specialized solutions to delivering enterprise-class SaaS tools. Precision Suite aligns our expertise with our mission to deliver scalable, impactful solutions that redefine what's possible in life sciences and healthcare today.'
Precision Explorer™ and Precision Trials™ will be available beginning June 30, 2025. Precision GTM™ will follow with availability by July 31, 2025. With these solutions, ConcertAI solidifies its position as the leader in generative and agentic AI tailored for oncology and broader life sciences applications.
About ConcertAI:
ConcertAI is the leader in predictive and generative AI SaaS and real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai™ technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers, and medical societies. TeraRecon provides advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT. CancerLinQ® is an initiative of ConcertAI, providing oncology providers with ASCO-aligned automated QOPI and ASCO Certified® quality solutions and SmartLinQ™ analytic services. Headquartered in Cambridge, Massachusetts, ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo. For more information, visit us at concertai.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
9 minutes ago
- Business Wire
Genesco Inc. to Present at the Goldman Sachs 32
NASHVILLE, Tenn.--(BUSINESS WIRE)--Genesco Inc. (NYSE: GCO) today announced that its management team will present at the Goldman Sachs 32 nd Annual Global Retailing Conference on Thursday, September 4, 2025. A webcast of the Genesco presentation is scheduled to begin at 8:55 a.m. (Eastern time) and may be accessed through Company's investor relations page at About Genesco Inc. Genesco Inc. (NYSE: GCO) is a footwear focused company with distinctively positioned retail and lifestyle brands and proven omnichannel capabilities offering customers the footwear they desire in engaging shopping environments, including more than 1,250 retail stores and branded e-commerce websites. Its Journeys, Little Burgundy and schuh brands serve teens, kids and young adults with on-trend fashion footwear inspired by youth culture in the U.S., Canada and the U.K. Johnston & Murphy serves the successful, affluent men and women with premium footwear, apparel and accessories in the U.S. and Canada, and Genesco Brands Group sells branded lifestyle footwear to leading retailers under licensed brands including Wrangler, Dockers, Starter and PONY. Founded in 1924, Genesco is based in Nashville, Tennessee. For more information on Genesco and its operating divisions, please visit
Business Wire
9 minutes ago
- Business Wire
Movado Group, Inc. Announces Date of Conference Call and Webcast for Second Quarter Fiscal Year 2026 Results
BUSINESS WIRE)--Movado Group, Inc. (NYSE: MOV) invites investors to listen to a broadcast of the Company's conference call to discuss second quarter fiscal year 2026 earnings results on Thursday, August 28, 2025, at 9:00 a.m. Eastern Time. A press release detailing the Company's second quarter fiscal year 2026 results will be issued before the market opens and prior to the call. The conference call will be hosted by Efraim Grinberg, Chairman and Chief Executive Officer, and Sallie DeMarsilis, Executive Vice President and Chief Financial Officer. Investors and analysts interested in participating on the call are invited to dial (877) 407-0784 and reference conference ID number 13755528 approximately ten minutes prior to the start of the call. The conference call will also be webcast live at The webcast will be archived online within one hour of the completion of the conference call and remain available for 90 days. Additionally, a telephonic re-play of the call will be available at 1:00 p.m. ET on August 28, 2025, until 11:59 p.m. ET on September 11, 2025 and can be accessed by dialing (844) 512-2921 and entering replay pin number 13755528. Movado Group, Inc. designs, sources, and globally distributes and sells MOVADO®, MVMT®, OLIVIA BURTON®, EBEL®, CONCORD®, CALVIN KLEIN®, COACH®, TOMMY HILFIGER®, HUGO BOSS® and LACOSTE® watches and, to a lesser extent, jewelry and other accessories, and operates Movado Company Stores in the United States and Canada.
Business Wire
9 minutes ago
- Business Wire
lululemon athletica inc. Announces Second Quarter Fiscal 2025 Earnings Conference Call
VANCOUVER, British Columbia--(BUSINESS WIRE)--lululemon athletica inc. (NASDAQ: LULU) today announced that its financial results for the second quarter fiscal 2025 will be released Thursday, September 4, 2025. The company will host a conference call at 4:30 p.m. Eastern time to discuss the financial results. If you would like to participate in the call, please dial (833) 752-3550 or (647) 846-8290, if calling internationally, approximately 10 minutes prior to the start of the call. A live webcast of the conference call will be available online at: A replay will be made available online approximately 2 hours following the live call. About lululemon athletica inc. lululemon athletica inc. (NASDAQ:LULU) is a technical athletic apparel, footwear, and accessories company for yoga, running, training, and most other activities, creating transformational products and experiences that build meaningful connections, unlocking greater possibility and wellbeing for all. Setting the bar in innovation of fabrics and functional designs, lululemon works with yogis and athletes in local communities around the world for continuous research and product feedback. For more information, visit
